TNF抑制剂生物类似药研究的汇总分析:比较类风湿关节炎不同疾病活动状态下的影像学进展
汇总三项SB4、SB2和SB5(依那西普、英夫利西单抗和阿达木单抗的生物类似药)III期研究,纳入1265例类风湿关节炎患者,按DAS28、SDAI和CDAI划分疾病活动状态,评估影像学进展。结果显示影像学进展总体较小,但随疾病活动度恶化而增加,高疾病活动度组影像学非进展者比例最低。
要点
- 第24/30周DAS28定义的缓解、LDA、MDA和HDA组1年mTSS平均变化分别为0.03、0.4、0.3和1.3。
- 以缓解组为参照,HDA组影像学非进展者OR最低(0.35,95%CI 0.23-0.54),MDA组为0.72(0.50-1.05),LDA组为0.90(0.55-1.48)。
- 使用SDAI或CDAI评估疾病活动度时观察到相似趋势,影像学进展总体较小但随疾病活动度恶化而增加。
核心结论
- 三项生物类似药研究的汇总分析显示,类风湿关节炎患者影像学进展总体较小,但随疾病活动度恶化而增加。
研究设计与样本
- 汇总三项III期研究(SB4、SB2、SB5,分别为依那西普、英夫利西单抗和阿达木单抗的生物类似药),纳入有影像学数据的患者共1265例。
主要发现
- 所有治疗合并后,第24/30周DAS28定义的缓解、LDA、MDA和HDA组1年mTSS平均变化分别为0.03、0.4、0.3和1.3。
- 第24/30周DAS28定义的缓解、LDA、MDA和HDA组影像学非进展者比例分别为79.8%、78.1%、74.1%和58.4%。
- 以缓解组为参照,影像学非进展者比例的OR在HDA组最低(0.35,95%CI 0.23-0.54),其次为MDA组(0.72,95%CI 0.50-1.05)和LDA组(0.90,95%CI 0.55-1.48)。
- 使用SDAI或CDAI评估疾病活动度时观察到相似趋势。
关键数值与推荐
- 疾病活动状态依据DAS28(基于红细胞沉降率)、SDAI和CDAI在不同时间点确定,分组为缓解、LDA、MDA和HDA。
- 影像学进展以改良总Sharp评分(mTSS)平均变化和影像学非进展者比例描述性汇总,OR比较使用逻辑模型。
临床怎么用
- 临床中应重视疾病活动度控制,尤其高疾病活动度患者影像学进展风险较高,需积极治疗以降低进展风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the relationship between disease activity and radiographic progression in rheumatoid arthritis, three phase III studies of SB4, SB2 and SB5 (biosimilars of etanercept, infliximab and adalimumab) were pooled to assess radiographic progression by disease activity status. METHODS: Patients from each study with radiographic data were pooled and grouped based on disease activity state (remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA)), determined by disease activity score based on 28-joint count (DAS28) per erythrocyte sedimentation rate, Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) at different time points. Mean change in modified Total Sharp Score (mTSS) and the proportion of radiographic non-progressors of higher disease activity groups (LDA, MDA and HDA) in reference to remission were summarised descriptively, with comparison of ORs using logistic models. RESULTS: 1265 patients were included. In all treatments combined, the 1 year mean change in mTSS was 0.03, 0.4, 0.3 and 1.3 and proportion of radiographic non-progressors was 79.8%, 78.1%, 74.1% and 58.4% in the week 24/30 DAS28-determined remission, LDA, MDA and HDA groups, respectively. ORs (95% CIs) of the proportion of non-progressors were lowest in the HDA group in reference to remission (0.35 (0.23 to 0.54)), followed by MDA (0.72 (0.50 to 1.05)) and LDA (0.90 (0.55 to 1.48)) groups. Similar trends were observed when disease activity was assessed using SDAI or CDAI. CONCLUSION: A pooled analysis of radiographic assessment data from three biosimilar studies showed that radiographic progression is small overall but increases with worse disease activity. TRIAL REGISTRATION NUMBERS: NCT01895309, NCT01936181 and NCT02167139.
引用
- Smolen JS, Choe JY, Weinblatt ME, et al. Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open. 2020. PMID: 31958281. doi:10.1136/rmdopen-2019-001096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。